128 related articles for article (PubMed ID: 37815914)
1. MYC is a regulator of androgen receptor inhibition-induced metabolic requirements in prostate cancer.
Crowell PD; Giafaglione JM; Jones AE; Nunley NM; Hashimoto T; Delcourt AML; Petcherski A; Agrawal R; Bernard MJ; Diaz JA; Heering KY; Huang RR; Low JY; Matulionis N; Navone NM; Ye H; Zoubeidi A; Christofk HR; Rettig MB; Reiter RE; Haffner MC; Boutros PC; Shirihai OS; Divakaruni AS; Goldstein AS
Cell Rep; 2023 Oct; 42(10):113221. PubMed ID: 37815914
[TBL] [Abstract][Full Text] [Related]
2. NDRG2 acts as a negative regulator downstream of androgen receptor and inhibits the growth of androgen-dependent and castration-resistant prostate cancer.
Yu C; Wu G; Li R; Gao L; Yang F; Zhao Y; Zhang J; Zhang R; Zhang J; Yao L; Yuan J; Li X
Cancer Biol Ther; 2015; 16(2):287-96. PubMed ID: 25756511
[TBL] [Abstract][Full Text] [Related]
3. Androgen-induced expression of DRP1 regulates mitochondrial metabolic reprogramming in prostate cancer.
Lee YG; Nam Y; Shin KJ; Yoon S; Park WS; Joung JY; Seo JK; Jang J; Lee S; Nam D; Caino MC; Suh PG; Chan Chae Y
Cancer Lett; 2020 Feb; 471():72-87. PubMed ID: 31838085
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor promotes ligand-independent prostate cancer progression through c-Myc upregulation.
Gao L; Schwartzman J; Gibbs A; Lisac R; Kleinschmidt R; Wilmot B; Bottomly D; Coleman I; Nelson P; McWeeney S; Alumkal J
PLoS One; 2013; 8(5):e63563. PubMed ID: 23704919
[TBL] [Abstract][Full Text] [Related]
5. Conversion of androgen receptor signaling from a growth suppressor in normal prostate epithelial cells to an oncogene in prostate cancer cells involves a gain of function in c-Myc regulation.
Vander Griend DJ; Litvinov IV; Isaacs JT
Int J Biol Sci; 2014; 10(6):627-42. PubMed ID: 24948876
[TBL] [Abstract][Full Text] [Related]
6. Supraphysiological Androgens Promote the Tumor Suppressive Activity of the Androgen Receptor through cMYC Repression and Recruitment of the DREAM Complex.
Nyquist MD; Coleman IM; Lucas JM; Li D; Hanratty B; Meade H; Mostaghel EA; Plymate SR; Corey E; Haffner MC; Nelson PS
Cancer Res; 2023 Sep; 83(17):2938-2951. PubMed ID: 37352376
[TBL] [Abstract][Full Text] [Related]
7. Plk1 Inhibition Enhances the Efficacy of BET Epigenetic Reader Blockade in Castration-Resistant Prostate Cancer.
Mao F; Li J; Luo Q; Wang R; Kong Y; Carlock C; Liu Z; Elzey BD; Liu X
Mol Cancer Ther; 2018 Jul; 17(7):1554-1565. PubMed ID: 29716963
[TBL] [Abstract][Full Text] [Related]
8. Increased Akt signaling resulting from the loss of androgen responsiveness in prostate cancer.
Dulinska-Litewka J; McCubrey JA; Laidler P
Curr Med Chem; 2013; 20(1):144-57. PubMed ID: 23033951
[TBL] [Abstract][Full Text] [Related]
9. Targeting the KDM4B-AR-c-Myc axis promotes sensitivity to androgen receptor-targeted therapy in advanced prostate cancer.
Tang DE; Dai Y; He JX; Lin LW; Leng QX; Geng XY; Fu DX; Jiang HW; Xu SH
J Pathol; 2020 Oct; 252(2):101-113. PubMed ID: 32617978
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA let-7c suppresses androgen receptor expression and activity via regulation of Myc expression in prostate cancer cells.
Nadiminty N; Tummala R; Lou W; Zhu Y; Zhang J; Chen X; eVere White RW; Kung HJ; Evans CP; Gao AC
J Biol Chem; 2012 Jan; 287(2):1527-37. PubMed ID: 22128178
[TBL] [Abstract][Full Text] [Related]
11. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
12. SREBF1 Activity Is Regulated by an AR/mTOR Nuclear Axis in Prostate Cancer.
Audet-Walsh É; Vernier M; Yee T; Laflamme C; Li S; Chen Y; Giguère V
Mol Cancer Res; 2018 Sep; 16(9):1396-1405. PubMed ID: 29784665
[TBL] [Abstract][Full Text] [Related]
13. NF-κB2/p52:c-Myc:hnRNPA1 Pathway Regulates Expression of Androgen Receptor Splice Variants and Enzalutamide Sensitivity in Prostate Cancer.
Nadiminty N; Tummala R; Liu C; Lou W; Evans CP; Gao AC
Mol Cancer Ther; 2015 Aug; 14(8):1884-95. PubMed ID: 26056150
[TBL] [Abstract][Full Text] [Related]
14. Dual targeting of androgen receptor and mTORC1 by salinomycin in prostate cancer.
Mirkheshti N; Park S; Jiang S; Cropper J; Werner SL; Song CS; Chatterjee B
Oncotarget; 2016 Sep; 7(38):62240-62254. PubMed ID: 27557496
[TBL] [Abstract][Full Text] [Related]
15. Targeting KDM4B that coactivates c-Myc-regulated metabolism to suppress tumor growth in castration-resistant prostate cancer.
Wu MJ; Chen CJ; Lin TY; Liu YY; Tseng LL; Cheng ML; Chuu CP; Tsai HK; Kuo WL; Kung HJ; Wang WC
Theranostics; 2021; 11(16):7779-7796. PubMed ID: 34335964
[No Abstract] [Full Text] [Related]
16. Targeting the fibroblast growth factor pathway in molecular subtypes of castration-resistant prostate cancer.
Labrecque MP; Brown LG; Coleman IM; Nguyen HM; Dalrymple S; Brennen WN; Isaacs JT; Li D; Lakely B; DeLucia DC; Lee JK; Schweizer MT; Lin DW; Corey E; Nelson PS; Morrissey C
Prostate; 2024 Jan; 84(1):100-110. PubMed ID: 37796107
[TBL] [Abstract][Full Text] [Related]
17. Maintenance of MYC expression promotes de novo resistance to BET bromodomain inhibition in castration-resistant prostate cancer.
Coleman DJ; Gao L; Schwartzman J; Korkola JE; Sampson D; Derrick DS; Urrutia J; Balter A; Burchard J; King CJ; Chiotti KE; Heiser LM; Alumkal JJ
Sci Rep; 2019 Mar; 9(1):3823. PubMed ID: 30846826
[TBL] [Abstract][Full Text] [Related]
18. A long noncoding RNA connects c-Myc to tumor metabolism.
Hung CL; Wang LY; Yu YL; Chen HW; Srivastava S; Petrovics G; Kung HJ
Proc Natl Acad Sci U S A; 2014 Dec; 111(52):18697-702. PubMed ID: 25512540
[TBL] [Abstract][Full Text] [Related]
19. Androgen suppresses proliferation of castration-resistant LNCaP 104-R2 prostate cancer cells through androgen receptor, Skp2, and c-Myc.
Chuu CP; Kokontis JM; Hiipakka RA; Fukuchi J; Lin HP; Lin CY; Huo C; Su LC; Liao S
Cancer Sci; 2011 Nov; 102(11):2022-8. PubMed ID: 21781227
[TBL] [Abstract][Full Text] [Related]
20. Androgen receptor signaling regulates the transcriptome of prostate cancer cells by modulating global alternative splicing.
Shah K; Gagliano T; Garland L; O'Hanlon T; Bortolotti D; Gentili V; Rizzo R; Giamas G; Dean M
Oncogene; 2020 Sep; 39(39):6172-6189. PubMed ID: 32820253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
